Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus VELOSEF 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus VELOSEF 250.
CEFTAROLINE FOSAMIL vs VELOSEF '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
600 mg IV every 12 hours infused over 1 hour
250 mg orally every 6 hours for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
1.2-1.5 hours in normal renal function; prolonged in renal impairment (up to 10-20 hours in ESRD)
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); remainder biliary/fecal (<10%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic